Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Clinical Trial of TQF6422 Injection to Evaluate Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles Following Single and Multiple Ascending Doses in Healthy Overweight or Obese Subjects.

NCT07794111 is registered in ClinicalTrials.gov with Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. as lead sponsor.

NCT NCT07794111
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07794111 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Clinical Trial of TQF6422 Injection to Evaluate Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profiles Following Single and Multiple Ascending Doses in Healthy Overweight or Obese Subjects.
Lead sponsor
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase
Phase 1
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
June 30, 2028
Enrollment
108 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity / overweight